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Abstract
Recent advances in proteomics have facilitated the analysis of the kinome ‘en masse’. What these
studies have revealed is a surprisingly dynamic network of kinase responses to highly selective
kinase inhibitors, thereby illustrating the complex biological responses to these small molecules.
Moreover these studies have identified key transcription factors, such as c-Myc and FOXO
(forkhead box O), that play pivotal roles in kinome reprogramming in cancer cells. Since many
kinase inhibitors fail despite a high efficacy of blocking their intended targets, elucidating kinome
changes at a more global level will be essential to understanding the mechanisms of kinase
inhibitor pharmacology. The development of technologies to study the kinome, as well as
examples of kinome resilience and reprogramming, will be discussed in the present review.
INTRODUCTION
“For every reaction there is an equal and opposite reaction”. The Third Law of Motion, as
first proposed by Sir Isaac Newton in 1687, describes the nature of forces between two
bodies. Quite possibly, this same principle may apply to the dynamic properties of the cell
signalling networks mediated by the human kinome. The human kinome or collection of 518
protein kinases [1], is proving to be a highly dynamic network of signalling enzymes
capable of rapidly responding and remodelling to selective pressures. There are now
numerous examples of kinome adaptation circumventing the effects of selective kinase
inhibitors, thereby facilitating the resilience of the kinome to inhibition [2,3]. Moreover,
multiple mechanisms of feedback inhibition and kinase cross-talk have been identified as
checkpoints in virtually every kinase signalling network. Not surprisingly, disruption of
these feedback circuits or alterations in patterns of kinase cross-talk has significant effects
on the kinome as a whole [4]. Specific kinase inhibitors have distinct effects on relieving
feedback inhibition, depending on the kinases targeted. In several cases, including B-Raf
and PKC (protein kinase C), kinase inhibitors cause paradoxical activation of kinases that
they were originally designed to inhibit [5,6]. Importantly, adaptations of the kinome as such
may ultimately determine the success or failure of these compounds as therapeutic agents.
Hence a comprehensive understanding of the details of kinome adaptation or remodelling in
response to activators and inhibitors is crucial to understanding the mechanisms of drug
action and/or acquired drug resistance.
Kinomics can be described as the study of kinases ‘en masse’. The term kinomics was first
published by Vieth et al. [7] in 2004 who proposed a chemogenetics approach to structurally
characterize the kinome. While genomics-based analyses of the kinome are well established,
only relatively recently have developments in proteomics technologies permitted the study
of the kinome at the protein level [8]. Principal among these methods are new quantitative
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MS-based approaches that allow large-scale studies of kinase expression and activation.
Improved methods of kinase enrichment now permit the study of the expressed and activated
kinome, providing a significant advantage over that of genomics alone. Combined with
advanced methods of phosphoproteomics, a highly sophisticated view of the kinome and its
related network of phosphoproteins is emerging [9].
Dysregulation of kinase signalling is central to the development of oncogenesis and drug
resistance. Hence protein kinases have been identified as some of the most attractive
pharmaceutical targets for a variety of diseases, including cancer and diabetes [10–12].
However a major impediment to the successful application of single kinase inhibitors is the
development of acquired drug resistance. This can occur through a multitude of
mechanisms, including kinase mutations or overexpression of specific kinases. For an
excellent up-to-date overview of this topic the readers are referred to the review by Barouch-
Benton and Sauer [13]. Less well understood is how changes in the activity of any single
kinase perturbs the kinome or how changes in the kinome can be specifically measured or
quantified. Moreover changes in kinome activity are predicted to influence protein–protein
interactions and function of kinase scaffolds [14,15]. The objective of the present review is
to discuss recent methodological advances for studying the kinome, some recently
discovered examples of kinome adaptations to targeted kinase inhibitors and, finally, to
examine potential mechanisms involved in mediating kinome responses to selective
therapeutic agents.
NEW PROTEOMICS STRATEGIES TO STUDY THE KINOME
The philosophy of studying the kinome as a network of kinases or ‘kinomics’ was first
proposed by Johnson and Hunter in 2005 [16]. Initial efforts to study the kinome focused on
identifying kinase substrates through large-scale phosphoproteomic analyses [17]. However,
because of the massive complexity of the phosphoproteome, these studies have provided
only a partial insight into the detailed regulation of the kinome [18]. Some studies have
attempted to characterize the kinome through kinase activity assays [19]. However, a
limitation to this approach is the considerable assay development required to profile large-
scale changes in kinase activity. Recently, advances in proteomics and genomics
technologies have revolutionized the analysis of the human kinome itself as an entity. RNA-
seq analysis revealed that ~70% of the total kinome (370/518) is expressed in typical breast
cancer cell lines [20,21]. Other studies performed extensive profiling of expressed kinases in
a large numbers of tissues [22] or specific cancers [23]. Despite this information, important
questions remain. For instance, how many of these kinases are active and how does the
activity of the kinome change in response to different stimuli or inhibitors? Moreover, how
does one study the untargeted or understudied members of the kinome where well-
characterized reagents are lacking?
Advances in kinase enrichment have greatly facilitated the ability to study the kinome [24].
On the basis of the original method of Haystead et al. [25] using γ-phosphoryl-linked ATP-
affinity columns to capture kinases, Knockaert et al. [26,27] were the first to demonstrate the
utility of immobilized kinase inhibitors. Daub and co-workers [28] refined this approach by
using a broad range of immobilized kinase inhibitors coupled to Sepharose beads. An
inherent advantage of the latter approach is the nanomolar affinity binding of kinases to the
inhibitor beads, thereby permitting efficient capture of a large fraction of the kinome. In
addition, by increasing the diversity of the coupled inhibitors, a greater diversity of kinases
could be captured [29]. Initially this technology was used to profile kinase inhibitor
selectivity and identify new cellular targets for select kinase inhibitors such as SB203580,
gefitinib, SU6668 and others [30–33]. Termed ‘Kino-Beads’ [34], this method was
commercialized (Axxima, Cellzome, Ambit) and broadly applied to assess kinase inhibitor
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specificity across the kinome [29,34–37]. For example, Bantscheff et al. [34] performed
quantitative analysis of the kinase targets for imatinib, dasatinib and bosutinib in K562
leukaemia cells. Similar studies have compared the selectivity of nilotinib and second-
generation dual Abl/SFK (Src family kinase) inhibitors [38,39]. Others used this technology
to compare the binding affinity of 38 kinase inhibitors across a panel of 317 kinases [36].
Importantly these papers marked some of the first studies to evaluate the specificity of
structurally distinct inhibitors against large numbers of kinases in the kinome. The results of
these and other studies demonstrated exquisite specificity for some inhibitors (lapatinib),
whereas others [staurosporine, sunitinib, lestaurtanib (PKC412) and dasatinib] lacked
specificity and bound many kinases from various kinase families [36,40].
More recent studies expanded this technology to profile changes in the kinome itself.
Multiple investigators have used this strategy to demonstrate cell-type-specific sets of
expressed kinomes using the immobilized inhibitors combined with LC (liquid
chromatography)-MS/MS (tandem MS), phosphoproteomics analysis and quantitative MS
[35,41,42]. In an interesting application, Daub et al. [43] used this approach to profile the
change in the kinome from S- and M-phase-arrested cells. Specifically, the authors
quantified over 219 kinases, identified over 1000 phosphorylation sites and identified
multiple kinases not previously associated with mitotic progression.
Single kinase inhibitors have limited success as cancer therapies because tumours evade
their action by activating alternative survival pathways, promoting acquired drug resistance
[15]. As such, the requirement for effective combination therapies has become increasingly
clear [44]. Until recently there has been no discovery mechanism to define the dynamic
activity of the kinome in response to inhibitors. Typically studies of kinome adaptation have
relied on immunoblotting of select kinases or the use of phosphoantibody arrays to assess
kinome changes [45]. However, these methods are limited by phosphoantibody availability
and specificity, and therefore limit the scale of analysis. An alternative approach is the
chemoproteomics method described by Patricelli et al. [46,47]. This method involves
covalently ‘tagging’ activated kinases with acyl phosphate derivatives and large-scale
identification of activated kinases by a targeted LC-MS approach. An advantage of this
approach is that inhibitor responses and inhibitor binding values can be established for
kinases in the native cellular context [48]. However, the requirement for sophisticated
methods of targeted MS limit the widespread application of this technology. Lastly, new
technologies, such as mass cytometry, hold great promise for the highly sensitive detection
of select members of the kinome and inhibitor responses in single cells [49,50]. Again, like
the antibody array approach, these methods are dependent on highly specific antibodies to
kinases and kinase phosphorylation sites.
Recently, Duncan et al. [21] applied a chemical proteomics approach that couples kinase
affinity capture with qMS (quantitative MS), providing a platform to profile global kinome
activity in response to targeted therapies. Using a derivation of the original Daub approach
[43], Duncan et al. [21] showed that changes in the expression or activation state of kinases
could be selectively enriched using a cocktail of MIBs (multiplexed inhibitor beads) (Figure
1) [21]. Isolation of endogenous protein kinases from different cell types was carried out
using MIBs consisting of multiple immobilized kinase inhibitors arranged in an inhibitor
specificity gradient (specific→non-specific). Specific kinase inhibitors form the top layers
of the MIBs, acting as a filter for abundant kinases. This critical pre-clearance step allows
the subsequent retention of low-abundance kinases on the non-specific pan-kinase inhibitor
beads. MIB-bound kinases are identified by off-line LC separation and high throughput
MALDI (matrix-assisted laser-desorption ionization)–TOF (time-of-flight)/TOF-MS. An
advantage of this approach is the large numbers of peptides quantified with high statistical
confidence. Moreover, phosphorylation of MIB-enriched kinases can be simultaneously
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determined by titanium dioxide enrichment and LC-MS. Thus these methods combine
kinase affinity capture with qMS and phosphoproteomics, providing a systems-wide
approach to profile global kinome activity (Figure 1).
A current challenge is to develop methods to study the untargeted or understudied kinome
[51]. In this regard, the MIB strategy works remarkably well. Using MIBs, hundreds of
kinases are enriched and quantified from across the spectrum of kinases, many of which
have been barely studied due to a lack of reagents [21]. Kinases from all major kinome sub-
families are captured, with a large percentage representing the understudied kinome.
Characterization of the properties of kinase binding to MIBs further revealed that three
factors determine binding: affinity, expression and kinase activity [21]. Thus MIB
technology captures the majority of the expressed kinome, as estimated by RNA-seq, and
can detect altered kinome activity profiles in response to stimuli or kinase inhibitors used to
treat cancer. As such these methods provide a comprehensive unbiased method to profile
changes in kinome remodelling or kinome adaptation to various cellular conditions or
inhibitors. The application of these methods to study kinome reprogramming or remodelling
in breast cancer is described below.
EXAMPLES OF KINOME RESILIENCE AND ADAPTATION TO INHIBITION
Raf kinase inhibitors and the activation of Raf/ERK (extracellular-signal-regulated kinase)
signalling in cells
Oncogenic mutations in the kinase B-Raf are common in malignant melanomas [52]. The
most frequent B-Raf mutation in melanoma is the V600E mutation and this, and other
activating B-Raf mutations, result in chronic activation of the MEK [MAPK (mitogen-
activated protein kinase)/ERK kinase]/ERK pathway, which is required for cell growth [53].
Consequently, small molecule inhibitors of Raf are attractive therapeutics for the treatment
of melanoma and other Raf-driven cancers [54]. Interestingly, studies uncovered a surprising
paradoxical resistance of Raf kinase signalling to select Raf inhibitors [55–57] (reviewed in
[5]). Raf kinase inhibitors (PLX4720, sorafenib and 885-A), while highly effective at
inhibiting mutant B-Raf, activated all three types of wild-type Raf (A, B and C) [55–57].
Using a chemical genetics approach, Poulikakos et al. [57] showed that inhibitor-mediated
dimerization was responsible for the paradoxical activation of Raf by PLX4032. This
compensatory activation is dependent on inhibitor binding to the ATP site of one Raf
molecule, which stimulates dimerization and activation of the drug-free Raf protomer. This
process requires Ras-GTP and stimulates growth through activation of the MAPK pathway
[55–57]. Moreover, N-Ras mutation or up-regulated PDGFB (platelet-derived growth factor
B) expression was shown to accompany the resistance of cells to PLX4032 [52]. Thus
despite efficacy at inhibiting mutant B-Raf in tumours, Raf inhibitors pose a risk of
enhancing Ras-dependent tumours through activation of wild-type Raf. In this regard, Raf
inhibitors have been shown to increase cutaneous cell carcinomas [58]. While these studies
provide an important cautionary example of the unexpected changes in the kinome in
response to single kinase inhibitors, they also illustrate the importance of elucidating kinome
responses to select inhibitors. As suggested from these findings, and observations that B-Raf
mutations or amplification facilitate the development of MEK inhibitor resistance [59–62],
strategies to co-target both Raf and MEK simultaneously have been proposed and tested
[63,64]. In support of this idea, recent studies from Greger et al. [65] have demonstrated that
co-targeting MEK and/or PI3K (phosphoinositide 3-kinase)/mTOR (mammalian target of
rapamycin) prevented the acquired resistance to the B-Raf inhibitor GSK2118436 and
suggest that co-targeting these two pathways is a viable strategy [65–67].
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Paradoxical activation of Raf/ERK by nilotinib and Abl kinase inhibitors
CML (chronic myelogenous leukaemia) is a myeloid cell cancer commonly caused by the
BCR-Abl fusion kinase oncogene [68]. While the majority of CML patients are successfully
treated by small molecule kinase inhibitors such as imatinib, nilotinib or dasatinib [69,70],
acquired drug resistance remains a problem, in particular mutation of the ‘gate-keeper’
residue (Thr315) of Abl (AblT315I), resulting in resistance to all three drugs [13,71].
Moreover, a recent study from Packer et al. [72] showed that these kinase inhibitors can
exert a paradoxical activation of B-Raf and C-Raf kinase in drug-resistant CML, similar to
that with the Raf kinase inhibitors described above. This response was also shown to require
the activity of Ras and resulted in the activation of the MEK/ERK pathway, albeit weaker
than that observed with the Raf kinase inhibitors [57]. The results of these studies
demonstrated that these compounds are weak Raf inhibitors and thereby induced Raf
dimerization as observed with PLX4032. In support of this, gatekeeper mutations in B-Raf
(T529N) and C-Raf (T421N) that prevent inhibitor binding, showed a lack of Abl inhibitor-
induced dimerization. Because of the observed paradoxical activation of Raf/MEK/ERK by
these compounds, the authors tested the synthetic lethality of a MEK inhibitor. Co-treatment
with the MEK inhibitor PD184352 blocked the nilotinib-induced activation of ERK and
strongly induced apoptosis of these cells, whereas PD184352 alone was without effect [72].
Thus these studies reveal an important and unexpected ‘off-target’ effect of Abl kinase
inhibitors on the MEK pathway and further illustrate the need to understand kinome
responses to single kinase inhibitors.
COT (cancer Osaka thyroid oncogene) as an activator of resistance to Raf inhibitors
COT/TPL2 (MAP3K8) is a MAPKKK (MAPK kinase kinase) capable of functioning at the
level of Raf [73]. To investigate the resistance to Raf kinase inhibitors in melanoma,
Johannessen et al. [74] expressed ~600 kinase and kinase-related ORFs (open reading
frames) and investigated resistance to Raf inhibitors (PLX4720) [74]. From these studies the
authors identified COT/TPL2 as an activator of MEK, whose expression promoted acquired
resistance to Raf inhibition. Furthermore, the authors demonstrated that COT/TPL2
expression facilitated the development of de novo Raf inhibitor resistance in B-Raf V600E
cell lines and samples from patients with metastatic B-Raf V600E melanoma. In biopsies of
relapsed tumours, COT/TPL2 (gene symbol MAP3K8) mRNA expression was increased,
providing further evidence for overexpression of this kinase in resistant melanoma.
Interestingly, COT/TPL2 expression also decreased sensitivity to MEK inhibitors
(AZD6244 and CI-1040). Because of the potential effects of COT in Raf mutant cells, the
authors suggest combinatorial treatments to target COT and MEK as a possible strategy to
prevent drug resistance. These studies and those of others provide additional support for co-
targeting Raf and MEK simultaneously [74,75].
PI3K inhibition activates ERK via HER (human epidermal growth factor receptor) 2 and/or
HER3 in breast cancer: importance of FOXO (forkhead box O) signalling
A sophisticated view of kinome feedback regulation has been gleaned from studies on PI3K
and Akt inhibitors. Of central importance is the role of feedback regulation of the mTOR
pathway [76]. Rapamycin-dependent inhibition of mTORC (mTOR complex) 1 relieves
feedback regulation of the IGF1R (insulin-like growth factor 1 receptor), thereby triggering
a compensatory activation of IGF1R and Akt targets such as the transcription factor FOXO
[77,78]. Because of the relationship between Akt and mTOR, it may not be surprising that
inhibition of Akt results in similar mechanisms of kinase reprogramming. Specifically,
Chandarlapaty et al. [79] showed that inhibition of PI3K/Akt relieved feedback inhibition
and increased the expression of a unique set of receptor tyrosine kinases including HER3,
IGF1R and the insulin receptor. In addition to expression, the phosphorylation of multiple
RTKs (receptor tyrosine kinases) was also stimulated by Akt inhibition. Treatment of cells
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with Akti (Akt inhibitor) 1/2 or Akti 1/2/3, resulted in up-regulation of RTK transcripts in a
FOXO-dependent manner. Given the significance of this RTK response, the authors tested
the combination of HER kinase inhibitors (lapatinib and Iressa) with Aktis in xenograft
models (BT-474 and NCI-H292) and showed that the combination of these inhibitors was
highly effective at inhibiting tumour growth. Chakrabarty et al. [80] also showed that
inhibition of PI3K with the small molecule inhibitor XL147 up-regulated the expression and
activation of multiple RTKs, including HER3, in a manner dependent on HER2 [80]. Again,
co-targeting the RTK response with trastuzumab or lapatinib was synergistic at inhibiting
growth, compared with the action of these inhibitors alone. Similarly, Serra et al. [81]
showed that the reactivation of HER signalling by PI3K/mTOR inhibition (BEZ235)
resulted in activation of HER2-dependent ERK activation. Consequent inhibition of MEK/
ERK with AZD6244 prevented this activation, and the combination of AZD6244 with
BEZ235 was highly effective at inhibiting tumour cell growth [81]. Thus these studies
exemplify the importance of elucidating the kinome feedback mechanisms and
understanding their implications for successful therapeutic applications.
A further extension of these studies examined the effects of mTORC1/2 inhibition. While
inhibition of mTORC1 with rapamycin leads to activation of Akt, ATP-competitive mTOR
kinase inhibitors (AZD8055) do not [82]. However as shown by these authors, despite initial
blockade of Akt phosphorylation (Thr308) through inhibition of mTORC2, the mTOR
inhibitors caused a biphasic response that resulted in a sustained inhibition of mTOR1
despite activation of Akt Thr308 phosphorylation. Consequently, treatment with mTOR
inhibitors reactivated Akt, again in a manner dependent on induced RTKs. Co-addition of
RTK inhibitors with mTOR inhibitors resulted in the enhanced inhibition of tumour growth.
Limitation of EGFR [EGF (epidermal growth factor) receptor] inhibitors: cross-talk between
EGFR and c-Met
Activation or mutation of the EGFR and downstream kinase pathways is common in GBM
(glioblastoma multiforma), colorectal cancer, NSCLC (non-small-cell lung carcinoma) and
TNBC (triple-negative breast cancer) [83]. This is often a result of EGFR mutations or
overexpression, hence EGFR inhibitors have been investigated as possible therapeutics in
these settings, with limited success [84,85]. Studies now demonstrate the difficulty of
targeting this RTK is due to secondary gatekeeper mutations (T790M) that prevent EGFR
inhibition or from activation of alternative RTKs following loss of EGFR activity. In
particular, several studies in EGFR-mutant NSCLC identify Met amplification and
activation as a mechanism for resistance to EGFR inhibitors, where Met amplification is
observed in 15–22% of NSCLC patient's tumours that were resistant to EGFR inhibitors
[86,87]. Multiple lines of evidence suggest that activated Met can compensate for EGFR
inhibition by partially protecting against loss of phospho-EGFR and contributing to
sustained activation of downstream growth signalling through ERK and Akt. A direct
association between EGFR and Met has been observed, although it is unclear how this
heterodimerization contributes to EGFR inhibitor resistance [88]. In such cases where Met is
induced as a mechanism of EGFR inhibitor resistance, co-treatment with EGFR and Met
inhibitors synergistically inhibited proliferation of cell lines, prevented tumour growth, and
induced apoptosis in cell and tumour models. Similar studies demonstrate the remarkable
plasticity of Met signalling in response to expression of EFGR mutations (de2-7 EGFR) in
GBM [89].
While it has been shown that EGFR inhibitor treatment can select for cells with pre-existing
Met amplification, it is also evident that loss of EGFR activity can rapidly induce
compensatory expression/activation of Met and other tyrosine kinases, including FGFR
(fibroblast growth factor receptor) 2 and SFKs [90–93]. This induced kinase activity is
independent on genetic mutation or amplification, and probably results, in part, from loss of
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negative-feedback regulation of suppressed kinases. Additionally, acute loss of upstream
kinase signalling can trigger changes in transcription factor stability and/or activity that lead
to induced expression of RTKs and their ligands. This was exemplified by Ware et al. [91],
who defined loss of ERK activity downstream of EGFR inhibition as causal in de-repression
of FGFR2/3 expression in NSCLC cell lines. These data demonstrate the diverse
mechanisms of plasticity and resistance in the kinome of tumour cells under the selective
pressure of targeted kinase inhibitors. With most oncogenic RTKs (such as EGFR) driving
cell growth through conserved kinase signalling pathways, there is a high potential for
cancer cells to circumvent targeted inhibition of any RTK by induced expression or activity
of alternative kinases.
Cross-talk between Raf and LKB1
The LKB1/AMPK (AMP-activated protein kinase)/mTOR pathway is a major metabolic
network that connects the cellular energy status to the regulation of protein synthesis and
key metabolic events [94,95]. Activation of AMPK by LKB1 provides a braking mechanism
to arrest protein synthesis through mTOR inactivation when cells are under energy stress or
low energy. Hence studies have focused on the tumour suppressive activity of LKB1 [96].
Loss of this suppressive function in LKB1–/– cells or transformed cells results in an
uncoupling of protein synthesis from growth signals [97]. Previous studies have shown that
oncogenic B-Raf inhibits the tumour suppressor activity of LKB1 through phosphorylation
[98]. In response to EGF or in B-Raf V600E melanoma cells, LKB1 is phosphorylated on
Ser325 and Ser428 in an ERK- and RSK (ribosomal S6 kinase)-dependent manner
respectively. Interestingly, this phosphorylation appears to disrupt the LKB1–AMPK
complex and the ability of cells to respond to nutrient stress [97]. As such, B-Raf or Ras
tumour cells may escape a major metabolic regulatory control mechanism. In support of this,
expression of a phosphorylation-deficient LKB1 (S325A/S428A), inhibited the proliferation
of melanoma cells [98]. Inhibition of MEK or RSK restored this regulatory switch by
preventing the phosphorylation of LKB1 and maintaining AMPK regulation. Interestingly
these studies suggest that an unexpected benefit of MEK inhibitors may be to restore this
important metabolic checkpoint.
MEK inhibition, c-Myc stability and RTK reprogramming in TNBC
Kinase inhibitors often fail in cancer treatment because tumours evade their action by
activating alternative survival pathways promoting drug resistance. This is a particular
problem for TNBC which is among some of the most drug-resistant cancers. As such, a
requirement for effective combination therapies has become increasingly evident; however,
defining the response of the kinome ‘en masse’ to molecular therapy has historically been
challenging. Recently, Duncan et al. [21] developed and utilized an innovative chemical
proteomics approach (MIB/MS, described above), to define the dynamic reprogramming of
the kinome in response to small-molecule inhibitors. Using MIB/MS chemical proteomics,
Duncan et al. [21] evaluated kinome reprogramming of TNBC cells and tumours to MEK
inhibitors, which are currently in Phase I/II clinical trials for a number of cancers, including
TNBC. Interestingly, treatment of TNBC cell lines or a TNBC GEMM (genetically
modified mouse model) with the highly specific allosteric MEK inhibitor AZD6244 resulted
in rapid reprogramming of the kinome, with activation of multiple serine/threonine and
tyrosine kinases, overcoming the initial MEK/ERK inhibition. Induced expression and
activation of a number of pro-survival RTKs, including PDGFRβ (PDGF receptor β), AXL,
VEGFR2 (vascular endothelial growth factor receptor 2) and DDR1 (discoidin domain
receptor family, member 1) was observed within 24 h following MEK inhibitor treatment.
Generation of AZD6244-resistant TNBC cell lines demonstrated that the inhibitor-induced
RTK reprogramming was stable and accompanied by increased survival signalling through
the PI3K/AKT, JAK (Janus kinase)/STAT (signal transducer and activator of transcription)
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and MEK/ERK pathways. Intriguingly, MIB/MS studies revealed that both MEK1 and
MEK2 were initially inhibited by AZD6244; however, by 24 h MEK2 had escaped
inhibition, reactivating ERK signalling. Knockdown of MEK2 in the presence of MEK
inhibitor enhanced growth inhibition, suggesting that the TNBC cells acquired dependency
on MEK2 signalling. Escape of MEK2 from AZD6244 inhibition is thought to occur due to
two contributing factors: (i) MEK1, but not MEK2, is regulated by negative-feedback
phosphorylation by ERK1/2, and (ii) MEK inhibitors have been shown to preferentially
inhibit the inactive form of MEK1/2. Consequently, activation of upstream RTK signalling
pathways following MEK inhibition lead to accumulation of activated MEK2, increasing the
IC50 of AZD6244 for MEK2, and thus facilitating the reactivation of ERK signalling.
Defining how cancer cells rewire kinase networks in response to targeted inhibition of
kinases presents a challenge that can be largely addressed by quantitative chemical
proteomics, although elucidating the mechanisms of kinome reprogramming is far less
straightforward. Directed investigation of the effects of disrupted feedback loops and/or
signalling downstream of inhibited kinases must be implemented on a case-by-case basis.
For example, Duncan et al. [21] found that treatment of both TNBC cells and the C3Tag
TNBC GEMM with AZD6244 caused an acute loss of ERK activity, resulting in loss of
phosphorylation of c-Myc at Ser62, rapid degradation of c-Myc protein and disruption of
Myc-Max transcriptional activity (Figure 2). Destabilization of Myc-Max transcriptional
repressor activity in response to MEK inhibition resulted in the induced expression and
activity of a number of RTKs. Knockdown of ERK1/2 or c-Myc using siRNA (small
interfering RNA) recapitulated the RTK activation by MEK inhibition, whereas stabilization
of c-Myc protein levels using proteasome inhibitor treatment or expression of proteasome-
resistant c-Myc mutants prevented activation of AZD6244-mediated RTKs. Collectively,
Duncan et al. [21] discovered a unique mechanism of MEK inhibitor resistance, where MEK
inhibition alleviates c-Myc-dependent repression of a number of pro-survival RTKs, leading
to reactivation of MEK/ERK signalling and subsequent resistance. These studies were
recapitulated with other MEK inhibitors (U0126 and GSK1120212) and demonstrate the
pivotal role of Myc in kinome reprogramming ([21] and J.S. Duncan, unpublished work)
(Figure 2).
Identification of kinases activated in response to MEK inhibition using MIB/MS led Duncan
et al. [21] to predict and test a novel combination therapy for treatment of TNBC. RNAi
(RNA interference)-mediated knockdown of PDGFRβ, VEGFR2, DDR1 and AXL in TNBC
cells in the presence of MEK inhibition enhanced growth inhibition, supporting RTK
reprogramming driving MEK inhibitor resistance. Targeting the AZD6244-induced RTKs
with the kinase inhibitor sorafenib synergistically enhanced growth inhibition and blocked
the AZD6244-mediated reactivation of the ERK pathway in TNBC cells. Importantly, co-
treatment of the TNBC GEMM with AZD6244 and sorafenib caused rapid tumour apoptosis
and significant tumour regression, whereas single agents were ineffective. Taken together,
Duncan et al. [21] used chemical proteomics to assess global kinome behaviour and its
response to small-molecule inhibitors, and identified a new and effective combination
therapy to treat TNBC.
SUMMARY
Recent methods have improved the ability to perform kinomics at a highly sophisticated and
unprecedented level. The combination of deep sequencing and proteomics technologies will
undoubtedly accelerate the analysis of kinome expression, activation and remodelling in
different cell systems and in response to therapeutics and other stimuli. This unique
opportunity will benefit clinicians and researchers alike who seek to evaluate the cellular
responses to select kinase inhibitors. As such, examples of kinome reprogramming are now
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evident. Inhibition of the major signalling pathways, Raf/MEK and PI3K initiates profound
kinome changes by altering the activity of transcription factors such as c-Myc and FOXO.
Defining how the kinome responds, including many of the untargeted or understudied
members, will be paramount to our understanding of the resilience of this important
signalling network to select inhibitors.
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Abbreviations used
Akti Akt inhibitor
AMPK AMP-activated protein kinase
CML chronic myelogenous leukaemia
COT cancer Osaka thyroid oncogene
DDR1 discoidin domain receptor family, member 1
EGF epidermal growth factor
EGFR EGF receptor
ERK extracellular-signal-regulated kinase
FGFR fibroblast growth factor receptor
FOXO forkhead box O
GBM glioblastoma multiforma
GEMM genetically modified mouse model
HER human epidermal growth factor receptor
IGF1R insulin-like growth factor 1 receptor
LC liquid chromatography
MAPK mitogen-activated protein kinase
MEK MAPK/ERK kinase
MIB multiplexed inhibitor bead
mTOR mammalian target of rapamycin
mTORC mTOR complex
NSCLC non-small-cell lung carcinoma
PDGF platelet-derived growth factor
PDGFRβ PDGF receptor β
PI3K phosphoinositide 3-kinase
qMS quantitative MS
RSK ribosomal S6 kinase
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RTK receptor tyrosine kinase
SFK Src family kinase
TNBC triple-negative breast cancer
TOF time-of-flight
VEGFR2 vascular endothelial growth factor receptor 2
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Figure 1. Monitoring kinome reprogramming in cells and tumours using MIBs in combination
with MS
Endogenous kinases are affinity-purified from cell lysates using MIB/MS and both MIB-
binding ratios and phosphorylation of kinase activation loops were determined using qMS.
Of the kinases identified in a recent study [21], only 4% are current targets for kinase
inhibitor drugs, the remainder representing the untargeted cancer kinome [51].
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Figure 2. Model describing the effects of targeted inhibition of MEK1/2 by AZD6244 in TNBC
Shown is the proposed kinome reprogramming caused by loss of c-Myc protein and
subsequent derepression of transcription of growth-promoting RTKs to reactivate MAPK
signalling as described in Duncan et al. [21].
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